TZIELD COMPASS program
Help your patients get access and support online or with the start form.
TZIELD COMPASS is a patient support program that helps eligible patients to gain access to TZIELD and provides them with education and resources related to TZIELD.
- Through our personalized program, patients will receive helpful tools and resources, information about financial assistance options, and additional support from the day of enrollment. Our team can also provide important reimbursement information and further education about TZIELD
- Once you and your patient have decided that TZIELD is right for them, the treatment journey begins. This resource outlines each of the key milestones and steps both you and your patient will take along the treatment path
Guiding your patients through the journey
A COMPASS Navigator will be there for your patient throughout their treatment with TZIELD. As an important resource throughout your patient’s treatment with TZIELD, the COMPASS Navigator can:
Prior to treatment
Help your patients get started
Help navigate the steps to product access, including prior authorizations, medical exceptions, appeals, and reauthorizations.
Help obtain access to the product
Offer education on product procurement through specialty pharmacy or Buy and Bill, as well as information about reimbursement.
Locate a site of care
Support you and your patient in locating site of care options for TZIELD infusions depending on their insurance and other factors.
Provide guidance on financial assistance
Provide information about financial assistance options that may be available to your patients, like the TZIELD Copay Program and Patient Assistance Program (PAP).
Provide guidance on insurance benefits
Explain how insurance benefits work to your patient and help them determine their potential out-of- pocket costs.
Answer questions
Answer any questions about the program and offerings.
After treatment
Handle post-care checkups
Perform additional check-ins with your patient once treatment is completed.
Downloadable resources
Insurance, coding, and billing
Detailed instructions on how to submit a patient copay claim and how patients can enrol in the copay program.
A resource that provides tips to help you draft a letter of appeal for your patients. A sample letter is provided for reference.
A resource that provides tips to help you draft a sample letter of necessity for your patients. A sample letter is provided for reference.
A quick reference sheet, include sample codes, related to coding and billing for TZIELD and its administration.
A detailed guide with helpful information related to coding and billing for TZIELD and its administration.
A checklist to help ensure you and your practice understand potential health plan prior authorization criteria to help prevent rejection and unnecessary delays.
Product distribution and ordering information
A document that includes information about distribution of TZIELD and how to order it.
A document that has considerations for placing a supply order for TZIELD infusions at home.
Understand your patient’s treatment path
Important Safety Information Anchor
INDICATION
TZIELD is a CD3-directed monoclonal antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
- Cytokine Release Syndrome (CRS): CRS occurred in TZIELD-treated patients during the treatment period and through 28 days after the last drug administration. Prior to TZIELD treatment, premedicate with antipyretics, antihistamines and/or antiemetics, and treat similarly if symptoms occur during treatment. If severe CRS develops, consider pausing dosing for 1 day to 2 days and administering the remaining doses to complete the full 14-day course on consecutive days; or discontinue treatment. Monitor liver enzymes during treatment. Discontinue TZIELD treatment in patients who develop elevated alanine aminotransferase or aspartate aminotransferase more than 5 times the upper limit of normal (ULN) or bilirubin more than 3 times ULN.
- Serious Infections: Use of TZIELD is not recommended in patients with active serious infection or chronic infection other than localized skin infections. Monitor patients for signs and symptoms of infection during and after TZIELD administration. If serious infection develops, treat appropriately, and discontinue TZIELD.
- Lymphopenia: Lymphopenia occurred in most TZIELD-treated patients. For most patients, lymphocyte levels began to recover after the fifth day of treatment and returned to pretreatment values within two weeks after treatment completion and without dose interruption. Monitor white blood cell counts during the treatment period. If prolonged severe lymphopenia develops (<500 cells per mcL lasting 1 week or longer), discontinue TZIELD.
- Hypersensitivity Reactions: Acute hypersensitivity reactions including serum sickness, angioedema, urticaria, rash, vomiting and bronchospasm occurred in TZIELD-treated patients. If severe hypersensitivity reactions occur, discontinue TZIELD and treat promptly.
- Vaccinations: The safety of immunization with live-attenuated (live) vaccines with TZIELD-treated patients has not been studied. TZIELD may interfere with immune response to vaccination and decrease vaccine efficacy. Administer all age-appropriate vaccinations prior to starting TZIELD.
- Administer live vaccines at least 8 weeks prior to treatment. Live vaccines are not recommended during treatment, or up to 52 weeks after treatment.
- Administer inactivated (killed) vaccines or mRNA vaccines at least 2 weeks prior to treatment. Inactivated vaccines are not recommended during treatment or 6 weeks after completion of treatment.
ADVERSE REACTIONS
Most common adverse reactions (>10%) were lymphopenia, rash, leukopenia, and headache.
USE IN SPECIFIC POPULATIONS
- Pregnancy: May cause fetal harm.
- Lactation: A lactating woman may consider pumping and discarding breast milk during and for 20 days after TZIELD administration.
Please see full Prescribing Information, including patient selection criteria, and Medication Guide. View Important Safety Information page.
© 2025 Sanofi. All rights reserved. MAT-US-2503244-v1.0-04/2025
INDICATION
IMPORTANT SAFETY INFORMATION
INDICATION
TZIELD is a CD3-directed monoclonal antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
- Cytokine Release Syndrome (CRS): CRS occurred in TZIELD-treated patients during the treatment period and through 28 days after the last drug administration. Prior to TZIELD treatment, premedicate with antipyretics, antihistamines and/or antiemetics, and treat similarly if symptoms occur during treatment. If severe CRS develops, consider pausing dosing for 1 day to 2 days and administering the remaining doses to complete the full 14-day course on consecutive days; or discontinue treatment. Monitor liver enzymes during treatment. Discontinue TZIELD treatment in patients who develop elevated alanine aminotransferase or aspartate aminotransferase more than 5 times the upper limit of normal (ULN) or bilirubin more than 3 times ULN.
- Serious Infections: Use of TZIELD is not recommended in patients with active serious infection or chronic infection other than localized skin infections. Monitor patients for signs and symptoms of infection during and after TZIELD administration. If serious infection develops, treat appropriately, and discontinue TZIELD.
- Lymphopenia: Lymphopenia occurred in most TZIELD-treated patients. For most patients, lymphocyte levels began to recover after the fifth day of treatment and returned to pretreatment values within two weeks after treatment completion and without dose interruption. Monitor white blood cell counts during the treatment period. If prolonged severe lymphopenia develops (<500 cells per mcL lasting 1 week or longer), discontinue TZIELD.
- Hypersensitivity Reactions: Acute hypersensitivity reactions including serum sickness, angioedema, urticaria, rash, vomiting and bronchospasm occurred in TZIELD-treated patients. If severe hypersensitivity reactions occur, discontinue TZIELD and treat promptly.
- Vaccinations: The safety of immunization with live-attenuated (live) vaccines with TZIELD-treated patients has not been studied. TZIELD may interfere with immune response to vaccination and decrease vaccine efficacy. Administer all age-appropriate vaccinations prior to starting TZIELD.
- Administer live vaccines at least 8 weeks prior to treatment. Live vaccines are not recommended during treatment, or up to 52 weeks after treatment.
- Administer inactivated (killed) vaccines or mRNA vaccines at least 2 weeks prior to treatment. Inactivated vaccines are not recommended during treatment or 6 weeks after completion of treatment.
ADVERSE REACTIONS
Most common adverse reactions (>10%) were lymphopenia, rash, leukopenia, and headache.
USE IN SPECIFIC POPULATIONS
- Pregnancy: May cause fetal harm.
- Lactation: A lactating woman may consider pumping and discarding breast milk during and for 20 days after TZIELD administration.
Please see full Prescribing Information, including patient selection criteria, and Medication Guide. View Important Safety Information page.